Exploring Biosimilars and Early Intervention in Psoriatic Arthritis

This chapter details an upcoming European study examining patient-reported outcomes for CTP13, a biosimilar to infliximab. It also underscores findings from the Core Evitas Psoriatic Arthritis Pondyloarthritis Registry that advocate for early intervention with biologics and targeted DMARDs.